Related Experiment Video
Updated: Aug 1, 2026

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome
D R McCance1, D R Hadden, L Kennedy
1Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
Abstract:
Six consecutive patients with Cushing's disease were treated with the broad spectrum antifungal drug ketoconazole. Urinary cortisol levels rapidly fell to within the normal range in five of the six patients. Acute hypoadrenalism occurred in one patient, and nausea and pyrexia in three. Our experience with hepatotoxicity was different from that reported by others in that reversible hepatotoxicity was demonstrated in three patients within 7 to 12 days of treatment. Further work is required before ketoconazole can be recommended as a standard primary therapy for patients with Cushing's syndrome. Continuing vigilance for both hypoadrenalism and hepatotoxicity is essential in any patient being treated with this drug either for hypercortisolism or for other reasons.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cryptococcal Meningitis
Cushing Syndrome I: Introduction
Cushing Syndrome II: Pathophysiology
Diabetic Ketoacidosis l: Introduction
Diabetic Ketoacidosis ll: Pathophysiology

